Randomised clinical trial evaluates acarbose and canagliflozin for post-bariatric hypoglycaemia, suggesting further research is needed.
HypoBar I is the first randomised, placebo-controlled study of the treatment of PBH with acarbose or canagliflozin. Reduction in time below range was not achieved by either treatment; nevertheless, improvements in hypothesis-generating secondary findings merit further investigation and validation. EudraCT number 2022-000157-87.
No takes yet. Share an insight, caveat, or question.
Lobato et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: